The University of Pennsylvania’s Kiran Musunuru has received an R35 award from the National Heart, Lung, and Blood Institute totaling USD 1,137,435 in first-year costs to advance a multi-indication CRISPR base-editing program targeting cardiovascular disease, with a project period running through January 2033. The grant, issued under funding opportunity RFA-HL-26-002, supports translational research across three cardiovascular indications: atherosclerotic cardiovascular disease prevention via li

Indianapolis-headquartered SpectronRx announced it secured $85 million in financing from OrbiMed to expand medical isotope production and contract manufacturing capabilities at its Grissom Aeroplex campus near Bunker Hill, Indiana. According to the announcement, the investment will support expansion of its integrated radiopharmaceutical platform which combines isotope production, drug development, scale-up, and GMP manufacturing within a single network. SpectronRx said the funding will be used t

MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid ® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authorit

BOSTON--(BUSINESS WIRE)--SV Health Investors (“SVHI”), a healthcare and life sciences focused private investment firm, announced today the acquisition of EpiVax, Inc. Headquartered in Providence, RI, EpiVax is a leading bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech companies. EpiVax has been a pioneer in pre-clinical drug development for over 25 years, serving as a trusted scientific advisor to life sciences clients. EpiVax represents a new pl

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced th

FRIDAY, April 3, 2026 — Many folks think it’s OK to belt back a few extra rounds on Saturday night if they stay mostly sober during the week. But saving up your drinks for a single sitting could be a recipe for liver problems, new research suggests. A team at the University of Southern California’s Keck School of Medicine linked occasional heavy drinking to triple the risk of advanced liver fibrosis — a dangerous type of scarring that can lead to liver failure. Their findings — published April

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock o

Study highlights novel multi-mechanistic immunotherapy combination in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing, and durability of response across hard-to-treat tumors LEXINGTON, Mass.--(BUSINESS WIRE)-- $AGEN #AACR2026 -- Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be presented at the Americ

NEEDHAM, Mass. (April 3, 2026) — Trialt, a global clinical research organization (CRO) specializing in biostatistics, statistical programming, data management, and medical writing, announced a strategic collaboration with Viedoc , a global provider of cloud-based eClinical solutions. The collaboration is designed to help Sponsors accelerate timelines, strengthen data quality, and improve decision-making across clinical trials. Viedoc’s cloud-based platform unifies data capture, management, and

NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on March 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to five new employees, stock options to purchase an aggregate of 70,000 shares of the Company’s common stock, with a per share ex